Fans can purchase tickets for all upcoming Billy Joel shows on sites like Vivid Seats; the official on-sale for the Citi ...
As for the Aug. 21 Citi Field show, it will serve as the debut at the Mets’ new home for both Joel and Sting. Neither has played the Flushing venue since its 2009 opening. However, it won’t be ...
The New York Mets have found great success in free agency with Steve Cohen at the helm. However, one player has an idea to ...
to 'Piano Man' echoing throughout Citi Field regularly during games. We're looking forward to welcoming this native New Yorker home for his first concert at Citi Field.” ...
New York Mets starting pitcher Kodai Senga wishes the New York Mets were able to attract more Japanese players to the franchise, but believes that his counterparts, many of which who have signed with ...
“We’re looking forward to welcoming this native New Yorker home for his first concert at Citi Field.” Sting performs during a stop on his “Sting 3.0” tour at The Wiltern ...
NEW YORK — Billy Joel will play a concert at Citi Field on Aug. 21 alongside Sting, the performers announced Thursday. Tickets go on sale Feb. 14 at 10 a.m. A presale for Citi card holders will ...
Music icons Billy Joel and Sting are taking over New York for one night. Billy Joel and Sting will perform at Citi Field Stadium in Queen’s, N.Y. on Aug. 21, and you’re going to want to secure ...
Business Insider's personal finance team compared Citi savings accounts to the best high-yield savings accounts and found that they're standard offerings overall. Both Citi savings accounts pay ...
not long after being named the bank’s new chief. Fraser benefited firsthand from flexibility in an industry notorious for its grueling hours and rigidity. And since becoming the head of Citi ...
Pete Alonso #20 of the New York Mets reacts after hitting a walk-off three-run home run during the tenth inning against the Tampa Bay Rays at Citi Field... NEW YORK, NEW YORK - MAY 17: Pete Alonso ...
Citi launched its coverage of Cytokinetics (NASDAQ ... A prospects added to worries over the company’s plans to begin a new Phase 3 trial for its once rejected heart failure therapy omecamtiv.